AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27266861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert in primary care electronic medical records (EMRs) for 1 year
Number of subjects: 41442
Study 27266861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41442
Study 24732752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 116
Study 24732752 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluvastatin)
Number of subjects: 116
Study 22802220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (8‐ to 12‐week treadmill exercise program, target lactate 2.0±0.5 mmol/L)
Number of subjects: 50
Study 22802220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 50
Study 20447012 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 45
Study 20447012 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study 17903340 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (38 % fat, 22 % MUFA)
Number of subjects: 59
Study 17903340 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich diet (38 % fat, 20 % SFA)
Number of subjects: 59
Study 17903340 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (30 % fat, 55 % carbohydrate)
Number of subjects: 59
Study 16552651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (n: 17)
Number of subjects: 55
Study 16552651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (n: 18)
Number of subjects: 55
Study 16552651 — intervention group
Group type: COMPARATOR
Intervention: Control (n: 20)
Number of subjects: 55
Study 11792602 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 53
Study 11792602 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet
Number of subjects: 53
Study 11792602 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 53
Study 11792602 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test
Number of subjects: 53
Study 11792602 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake (protein and fat)
Number of subjects: 53
Study 10430379 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose octreotide (0.5 microg/kg/hr by continued i.v. infusion)
Number of subjects: 43
Study 10430379 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose octreotide
Number of subjects: 43
Study 10430379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 7582405 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Robert Jones Bandage (MRJB)
Number of subjects: 40
Study 7582405 — intervention group
Group type: COMPARATOR
Intervention: Elastic Support Bandage (ESB)
Number of subjects: 40
Study 2190515 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone, 60 mg/d for 7 days, followed by a progressive tapering over 14 days)
Number of subjects: 37
Study 2190515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2190515 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 37
Study 365800 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 30 microgram
Number of subjects: 10
Study 365800 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 40 microgram
Number of subjects: 10
Study 365800 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 20 microgram
Number of subjects: 10
Study 365800 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) 10 microgram
Number of subjects: 10
Study 365800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31987512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention (including sit-stand workstations, group sessions, activity/sitting trackers)
Number of subjects: 244
Study 31987512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention
Number of subjects: 244
Study 31987512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study 31230397 — intervention group
Group type: COMPARATOR
Intervention: H2 RAs
Number of subjects: 0
Study 31230397 — intervention group
Group type: COMPARATOR
Intervention: PPIs
Number of subjects: 0
Study 31230397 — intervention group
Group type: COMPARATOR
Intervention: Combined H2 RAs and PPIs
Number of subjects: 0
Study 29110647 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once-weekly
Number of subjects: 307
Study 29110647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 26283094 — intervention group
Group type: EXPERIMENTAL
Intervention: I Move (self-determination theory and motivational interviewing)
Number of subjects: 0
Study 26283094 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Plus (traditional health behavior theories)
Number of subjects: 0
Study 26283094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 23331534 — intervention group
Group type: EXPERIMENTAL
Intervention: PĒCO2 at hypoventilation (43 mmHg)
Number of subjects: 23
Study 23331534 — intervention group
Group type: EXPERIMENTAL
Intervention: PĒCO2 at normoventilation (33 mmHg)
Number of subjects: 23
Study 23331534 — intervention group
Group type: EXPERIMENTAL
Intervention: PĒCO2 at hyperventilation (23 mmHg)
Number of subjects: 23
Study 23331534 — intervention group
Group type: EXPERIMENTAL
Intervention: PĒCO2 at apnea
Number of subjects: 23
Study 20505438 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab 0.5 mg/kg
Number of subjects: 30
Study 20505438 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab 1.5 mg/kg
Number of subjects: 30
Study 20505438 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab 5.0 mg/kg
Number of subjects: 30
Study 20505438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (all doses)
Number of subjects: 30
Study 20505438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18389741 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted right hemicolectomy (LRH)
Number of subjects: 66
Study 18389741 — intervention group
Group type: COMPARATOR
Intervention: Open right hemicolectomy (ORH)
Number of subjects: 66
Study 17062427 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct trainer‐trainee interaction
Number of subjects: 83
Study 17062427 — intervention group
Group type: COMPARATOR
Intervention: Self‐paced computer‐assisted training
Number of subjects: 83
Study 17062427 — intervention group
Group type: COMPARATOR
Intervention: On‐line training with real‐time audio‐visual interaction
Number of subjects: 83
Study 14552502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 14552502 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 14552502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data
Number of subjects: 0
Study 11832135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin 1 microg x kg(‐1) x min(‐1) perioperatively
Number of subjects: 40
Study 11832135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 40
Study 1635566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine plus tamoxifen
Number of subjects: 117
Study 1635566 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 117
Study 6733563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous misonidazole with 10 fractions of 400 rad each
Number of subjects: 38
Study 6733563 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 38
Study 31387061 — intervention group
Group type: EXPERIMENTAL
Intervention: High Power Poses (HPP)
Number of subjects: 56
Study 31387061 — intervention group
Group type: COMPARATOR
Intervention: Low Power Poses (LPP)
Number of subjects: 56
Study 29605036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine PCA
Number of subjects: 20
Study 29605036 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone PCA
Number of subjects: 20
Study 26691888 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg thrice-daily for 6 months
Number of subjects: 39
Study 24508083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water cooling of tonsillar fossa and pharyngeal mucosa with 4 °C saline
Number of subjects: 40
Study 24508083 — intervention group
Group type: COMPARATOR
Intervention: No cooling (Control)
Number of subjects: 40
Study 22909799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-video-assisted thoracoscopy surgery (HVATS) esophagectomy
Number of subjects: 80
Study 22909799 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 80
Study 22909799 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Number of subjects: 80
Study 20444503 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy)
Number of subjects: 40
Study 20444503 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological treatment
Number of subjects: 40
Study 17903569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopharyngeal packing
Number of subjects: 144
Study 15625142 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl/estradiol plus 3 mg drospirenone (group A)
Number of subjects: 71
Study 15625142 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl/estradiol plus 75 microg gestodene (group B)
Number of subjects: 71
Study 15625142 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (group C)
Number of subjects: 71
Study 12413987 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT with IV injection of naloxone
Number of subjects: 21
Study 12413987 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 21
Study 12413987 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (estro‐progestin combined therapy)
Number of subjects: 21
Study 12413987 — intervention group
Group type: COMPARATOR
Intervention: OGTT (saline study)
Number of subjects: 21
Study 10207542 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 p24 antibody
Number of subjects: 218
Study 10207542 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 p24 antibody < 5 RTU
Number of subjects: 218
Study 10207542 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 RNA
Number of subjects: 218
Study 10207542 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell percentage
Number of subjects: 218
Study 10207542 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD p24 antigen
Number of subjects: 218
Study 8600093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial Thermoradiotherapy (ITRT)
Number of subjects: 173
Study 8600093 — intervention group
Group type: COMPARATOR
Intervention: Interstitial Radiotherapy (IRT)
Number of subjects: 173
Study 1876365 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler group (preliminary assessment by umbilical artery resistance estimation)
Number of subjects: 897
Study 1876365 — intervention group
Group type: COMPARATOR
Intervention: FHR group (preliminary assessment by computerized fetal heart rate analysis)
Number of subjects: 897
Study 7102442 — intervention group
Group type: EXPERIMENTAL
Intervention: Control over social evaluation (ability to critique the evaluation and evaluate their evaluator)
Number of subjects: 60
Study 7102442 — intervention group
Group type: COMPARATOR
Intervention: Threatened group without control
Number of subjects: 60
Study 7102442 — intervention group
Group type: COMPARATOR
Intervention: Nonthreatened group
Number of subjects: 60
Study 7102442 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluated group (received bogus evaluations)
Number of subjects: 60
Study 31984593 — intervention group
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement (Group FE)
Number of subjects: 22
Study 31984593 — intervention group
Group type: COMPARATOR
Intervention: No foraminal enlargement (Group NFE)
Number of subjects: 22
Study 30378288 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusions
Number of subjects: 0
Study 30378288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28388244 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, elotuzumab, carfilzomib, ixazomib, panobinostat
Number of subjects: 0
Study 28388244 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs in patients with relapsed and/or refractory MM
Number of subjects: 0
Study 28388244 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anti-MM drugs
Number of subjects: 0
Study 28388244 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies in the management of patients with newly diagnosed MM
Number of subjects: 0
Study 26691333 — intervention group
Group type: EXPERIMENTAL
Intervention: OM/AML/HCTZ 20/5/12.5
Number of subjects: 341
Study 26691333 — intervention group
Group type: COMPARATOR
Intervention: OM/HCTZ 20/12.5
Number of subjects: 341
Study 26691333 — intervention group
Group type: EXPERIMENTAL
Intervention: OM/AML/HCTZ 40/5/12.5
Number of subjects: 341
Study 24402285 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hexyl-1,3-phenylenediol
Number of subjects: 0
Study 24402285 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 22249393 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee enema (3 times weekly for 6 visits)
Number of subjects: 11
Study 22249393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral coffee consumption (2 times daily for 11 days)
Number of subjects: 11
Study 20305034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OC)
Number of subjects: 23
Study 20305034 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone-analogues (GnRH-a)
Number of subjects: 23
Study 17991642 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP group (fed formula with LCPs)
Number of subjects: 22
Study 17991642 — intervention group
Group type: COMPARATOR
Intervention: no-LCP group (fed formula without LCPs)
Number of subjects: 22
Study 15663548 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-oxacalcitriol (OCT) 5 microg, 10 microg, or 15 microg administered at the end of every HD for 12 weeks
Number of subjects: 203
Study 15663548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 203
Study 15663548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled OCT groups
Number of subjects: 203
Study 15663548 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose OCT groups
Number of subjects: 203
Study 12490683 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 239
Study 12490683 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 239
Study 9864806 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyoxidonium
Number of subjects: 56
Study 7895356 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 micrograms/100 mL per minute)
Number of subjects: 110
Study 7895356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1, 2, and 4 micrograms/100 mL per minute)
Number of subjects: 110
Study 1914396 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 200
Study 1914396 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 200
Study 6947984 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine digluconate (Group B)
Number of subjects: 40
Study 6947984 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 40
Study 6947984 — intervention group
Group type: COMPARATOR
Intervention: 600 ml placebo (Group C)
Number of subjects: 40
Study 6947984 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml 0.05% chlorhexidine digluconate (Group E)
Number of subjects: 40
Study 6947984 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml 0.05% chlorhexidine digluconate (Group D)
Number of subjects: 40
Study 31039250 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based (FB) intervention
Number of subjects: 249
Study 31039250 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only (PO) intervention
Number of subjects: 249
Study 31039250 — intervention group
Group type: COMPARATOR
Intervention: Health education condition (HEC)
Number of subjects: 249
Study 28693921 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple based coping intervention (CBCI)
Number of subjects: 132
Study 28693921 — intervention group
Group type: COMPARATOR
Intervention: Individual coping intervention (ICI)
Number of subjects: 132
Study 26449252 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-H.pylori treatment
Number of subjects: 919
Study 26449252 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-H.pylori followed by celecoxib treatment
Number of subjects: 919
Study 26449252 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 919
Study 23588574 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy (MRS)
Number of subjects: 32
Study 21328087 — intervention group
Group type: EXPERIMENTAL
Intervention: AS100‐1 antigens
Number of subjects: 508
Study 19152130 — intervention group
Group type: EXPERIMENTAL
Intervention: RegEx (regadenoson with low-level exercise)
Number of subjects: 60
Study 19152130 — intervention group
Group type: COMPARATOR
Intervention: PlcEx (placebo with low-level exercise)
Number of subjects: 60
Study 19152130 — intervention group
Group type: COMPARATOR
Intervention: AdenoSup (standard adenosine-supine protocol)
Number of subjects: 60
Study 18181512 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circulation (MECC System)
Number of subjects: 0
Study 18181512 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (ECC)
Number of subjects: 0
Study 15162156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management (analgesic treatment)
Number of subjects: 1021
Study 15162156 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessment using EORTC QLQ‐C30 and LC‐13
Number of subjects: 1021
Study 15162156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Management Index (PMI) evaluation
Number of subjects: 1021
Study 11252622 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple surrogate endpoints
Number of subjects: 0
Study 11252622 — intervention group
Group type: COMPARATOR
Intervention: Single biomarker as a surrogate
Number of subjects: 0
Study 9514373 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care approaches
Number of subjects: 146
Study 9514373 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 9514373 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 146
Study 7974754 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm transverse incision
Number of subjects: 181
Study 7974754 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 181
Study 2521988 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 50
Study 2521988 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 50
Study 334219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg
Number of subjects: 9
Study 334219 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 9
Study 334219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31070860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft (cellular matrix device)
Number of subjects: 56
Study 31070860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oasis (noncellular matrix device)
Number of subjects: 56
Study 31070860 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 56
Study 31070860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft
Number of subjects: 56
Study 31070860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oasis
Number of subjects: 56
Study 31070860 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 56
Study 27387372 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert for AFib intervention
Number of subjects: 80
Study 27387372 — intervention group
Group type: COMPARATOR
Intervention: Attention control session
Number of subjects: 80
Study 25894458 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-reduction external rotation immobilization (9 patients)
Number of subjects: 20
Study 25894458 — intervention group
Group type: COMPARATOR
Intervention: Post-reduction internal rotation immobilization (11 patients)
Number of subjects: 20
Study 23221375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for supervisors
Number of subjects: 340
Study 23221375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for workplace champions
Number of subjects: 340
Study 23221375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group (supervisors and workplace champions)
Number of subjects: 340
Study 23221375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 340
Study 20646904 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP recruitment (continuous positive airway pressure of 35 cm H(2)O for 40 seconds
Number of subjects: 16
Study 20646904 — intervention group
Group type: COMPARATOR
Intervention: Pressure control recruitment maneuver (PCRM) (pressure control ventilation with positive-end expiratory pressure of 15 cm H(2)O and pressure control above positive end-expiratory pressure of 35 cm H(2)O for 2 minutes)
Number of subjects: 16
Study 19616998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Number of subjects: 278
Study 19616998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate + Modafinil
Number of subjects: 278
Study 19616998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 19616998 — intervention group
Group type: COMPARATOR
Intervention: Modafinil
Number of subjects: 278
Study 17670803 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (postal bulletin plus outreach visit)
Number of subjects: 98
Study 17670803 — intervention group
Group type: COMPARATOR
Intervention: Postal bulletin
Number of subjects: 98